Radiotherapy and CTLA-4 Blockade Responses in Metastatic Lung Cancer

Clinical trial data from a study on combining focal radiation therapy with anti-CTLA-4 immunotherapy for chemo-refractory metastatic non-small-cell lung cancer. The study, authored by S. Formenti, reports objective responses in 18% of enrolled patients and disease control in 31%. It includes predictors like serum interferon-β levels and dynamic changes in blood T cell clones.

Use Cases

• Predicting treatment response based on serum interferon-β levels mentioned in the description
• Analyzing T cell clonal dynamics as a biomarker for immunotherapy efficacy
• Investigating mechanisms of radiation-induced neoantigen exposure to the immune system

Strengths

• Includes specific clinical outcome metrics: 18% objective response rate and 31% disease control rate
• Links clinical outcomes to mechanistic predictors like serum interferon-β and T cell clones

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download
• Last update date is unknown; freshness unverified

Provenance

Source

S. Formenti via paperswithcode

Collection Method

Clinical trial data from a study on metastatic NSCLC patients.